# Patient-Trial Match Report

*Generated: 2026-01-05 18:31:12*

## Patient Profile

- **Age**: 71
- **Sex**: Male
- **Cancer Type**: squamous cell lung cancer

**Clinical Description**:
> 71-year-old male with metastatic squamous cell lung cancer, no actionable driver mutations identified (EGFR/ALK/ROS1/BRAF wild-type, KRAS wild-type). PD-L1 TPS â‰¥90%. First-line pembrolizumab monotherapy achieved durable response for 22 months, now progressed with new contralateral lung nodules and mediastinal lymphadenopathy. Seeking second-line immunotherapy combinations or novel checkpoint approaches. Former heavy smoker (50 pack-years). COPD on inhalers, no supplemental O2. Mild CKD (eGFR 52). Motivated patient willing to travel for trials.

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 10
- **Total trials evaluated**: 100
- **Excluded by fast filter**: 98
- **LLM scored**: 2

## ðŸŸ¢ HIGH Likelihood (1 trials)

### [NCT04266730](https://clinicaltrials.gov/study/NCT04266730)

**Phase I Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Administered Concurrently With Pembrolizumab**

- **Sponsor**: UNC Lineberger Comprehensive Cancer Center
- **Phase**: Phase 1
- **Status**: Not yet recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has histologically confirmed squamous non-small cell lung cancer.
- ECOG status is 1.
- PD-L1 TPS is â‰¥90%.
- No active brain metastases.
- Age is over 18 and under 75.

**? Uncertainties:**
- Absence of specific lab results for absolute neutrophil count, absolute lymphocyte count, hemoglobin, platelet count, AST, ALT, total serum bilirubin, and creatinine clearance.

**Assessment:**
> The patient's cancer type matches the trial indication for squamous non-small cell lung cancer, and the line of treatment is appropriate since the patient has previously received pembrolizumab and is seeking second-line therapy. The main criteria are met, though organ function lab results are not provided.

---

## Excluded (99 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT02143830](https://clinicaltrials.gov/study/NCT02143830) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03474497](https://clinicaltrials.gov/study/NCT03474497) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03476681](https://clinicaltrials.gov/study/NCT03476681) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03786692](https://clinicaltrials.gov/study/NCT03786692) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03851445](https://clinicaltrials.gov/study/NCT03851445) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04155034](https://clinicaltrials.gov/study/NCT04155034) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04165070](https://clinicaltrials.gov/study/NCT04165070) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04499053](https://clinicaltrials.gov/study/NCT04499053) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04665206](https://clinicaltrials.gov/study/NCT04665206) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04868877](https://clinicaltrials.gov/study/NCT04868877) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04929028](https://clinicaltrials.gov/study/NCT04929028) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05058651](https://clinicaltrials.gov/study/NCT05058651) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05061550](https://clinicaltrials.gov/study/NCT05061550) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05098132](https://clinicaltrials.gov/study/NCT05098132) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05267626](https://clinicaltrials.gov/study/NCT05267626) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05388773](https://clinicaltrials.gov/study/NCT05388773) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05394831](https://clinicaltrials.gov/study/NCT05394831) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05443126](https://clinicaltrials.gov/study/NCT05443126) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05501665](https://clinicaltrials.gov/study/NCT05501665) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05519293](https://clinicaltrials.gov/study/NCT05519293) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| ... | *and 78 more* |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT05566223](https://clinicaltrials.gov/study/NCT05566223) | Intima Bioscience, I | Patient is 71 years old; trial requires participants to be age â‰¤ 70 years. |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| squamous cell lung cancer | manual | 1.0 |
| PD-L1 TPS â‰¥90% squamous cell lung cancer | llm | 0.9 |
| PD-L1 TPS â‰¥90% NSCLC | llm | 0.9 |
| squamous cell lung cancer PD-L1 TPS â‰¥90% | llm | 0.9 |
| NSCLC | llm | 0.8 |
| non-small cell lung cancer | llm | 0.8 |
| PD-L1 TPS â‰¥90% | llm | 0.9 |
| PD-L1 90% | llm | 0.9 |
| PD-L190% | llm | 0.8 |
| PD-L1-90% | llm | 0.8 |
